Skip to content

Circulating fibroblast growth factor 21 predicts adverse outcomes in patients with pre-heart failure and HFpEF.

Sep 2026 · Pathology, Research and Practice · Vol 288, pp. 156687 · 0 citations · 48 references
Medicine

TL;DR

It is demonstrated that circulating FGF21 acts as an independent predictor of recurrent heart failure and all-cause death in patients with HFpEF, and may serve as a promising auxiliary biomarker for risk stratification of patients with HFpEF in clinical practice.

Abstract

Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of patients with heart failure. Given its complex pathogenesis, non-invasive biomarkers are urgently needed. Fibroblast growth factor 21 (FGF21) modulates metabolism and inflammation, yet its prognostic role in the development and progression of HFpEF remains unclear. This observational study enrolled 609 patients with pre-heart failure, characterized predominantly by diastolic dysfunction, and 297 patients with HFpEF. Baseline FGF21 concentrations were measured. All enrolled patients underwent a median follow‑up of 3.5 years. Cox regression analyses demonstrated that FGF21 had limited predictive value for progression to HFpEF in patients with pre-heart failure. However, FGF21 independently predicted the composite endpoint of recurrent heart failure hospitalization and all-cause mortality among patients with HFpEF. The hazard ratios remained relatively stable across HFpEF patient subgroups stratified by age, BMI, hypertension, diabetes, NYHA class, and eGFR. In conclusion, our study demonstrates that circulating FGF21 acts as an independent predictor of recurrent heart failure and all-cause death in patients with HFpEF, and may serve as a promising auxiliary biomarker for risk stratification of patients with HFpEF in clinical practice.

View source

Similar papers

Open access Oct 2026

Statin treatment long-term prognostic impact and its association with immune-inflammatory biomarkers levels in acute heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) is characterized by diastolic dysfunction of left ventricle. There is evidence on the role of inflammation in the pathophysiology of HFpEF, however this knowledge is yet to be utilized in clinical practice. We conducted a study to evaluate the associat...

K. Stepien, P. Rostoff, A. Karcińska et al. · 0 citations
Open access Sep 2026

Fibroblast Growth Factor 23 and Outcomes in Acute Heart Failure

Worsening heart failure (WHF) is a complex clinical syndrome associated with a high risk of mortality and further decompensations, characterized by fluid overload and upregulated inflammatory and fibrotic processes linked to organ dysfunction. Fibroblast growth factor 23 (FGF23) is an emerging proxy of fibrosis and may...

A. Martí-Martínez, Julio Núñez, Herminio López-Escribano et al. · 0 citations
Nov 2026

miR-200c-3p: An Adjunct Chronic Heart Failure Risk Marker Modulating Cardiomyocyte Hypertrophic Transcription and Cardiac Fibroblast Fibrosis.

This study evaluated circulating microRNA-200c-3p (miR-200c-3p) for diagnosis and prognosis in chronic heart failure (CHF) and its regulatory roles in cardiomyocyte hypertrophy and myocardial fibrosis in vitro. A single-center prospective cohort included 150 CHF patients and 80 healthy controls, with CHF stratified int...

Fei Li, Bao-Feng Jiang · 0 citations
Open access Oct 2026

Prognostic impact of microvascular dysfunction and systemic inflammation in women with chronic heart failure

The combined assessment of coronary microvascular function and inflammatory biomarkers independently predicts adverse outcomes and improves risk stratification beyond conventional markers and highlights the importance of the inflammation–microvascular axis in heart failure pathophysiology in women.

D. Abidova, Jamol Uzokov, M. Uzakova · 0 citations
Open access Oct 2026

Association between early NLPR3 changes and outcomes after heart failure hospitalization in patients with heart failure and preserved ejection fraction

Heart failure (HF) remains a major cause of morbidity and mortality worldwide. HF with preserved ejection fraction (HFpEF) is a heterogeneous syndrome characterized by pathophysiological mechanisms distinct from reduced ejection fraction and is associated with a chronic, low-grade inflammatory state driven by com...

E. Santiago-Vacas, E. Revuelta-López, J. Núñez et al. · 0 citations
Open access Nov 2026

Prognostic Implications of High HFpEF Probability in Patients With Chronic Thromboembolic Pulmonary Hypertension

ABSTRACT Background Chronic thromboembolic pulmonary hypertension (CTEPH) and left heart disease, particularly heart failure with preserved ejection fraction (HFpEF), show overlapping clinical features despite distinct pathophysiology. Objectives The HFpEF‐ABA algorithm (age, body mass index, atrial fibrillation) was u...

Yi-Jia Wang, Xin Li, Z. Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.